Carboplatin-loaded surface modified-PLGA nanoparticles confer sustained inhibitory effect against retinoblastoma cell in vitro

Zhuang, Hua; Xu, Yanan; Zheng, Honghua; Huan, Yu-Rong; Zheng, Ning-Xuan; Lin, Lin; Zhang, Wu-Zhen; Xu, Wei

doi:10.5935/0004-2749.20220075

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Carboplatin-loaded PLGA and SA-PLGA were studied to investigate their antiproliferative effect on retinoblastoma cells. 32 Following 7 days after treatment in vitro, the authors observed significant intracellular uptake when compared to the control group. The study revealed an improved growth inhibitory effect when compared to native carboplatin.…”

Section: Effective Treatment Approachmentioning

confidence: 92%

See 1 more Smart Citation

An Overview of Nanoparticles for Treatment of Retinoblastoma: Disease Characteristics and Experimental Approaches

Patel

Conte

Luo

et al. 2022

MRAJ

View full text Add to dashboard Cite

Retinoblastoma is the most common type of eye cancer in infants and children. Probability of saving vision and survival depends upon two main factors: progression of the disease from unilateral to bilateral and severity of the disease. In order to effectively treat retinoblastoma and retain vision, it is crucial to focus treatment options on reducing toxicity and nonspecific targeting while enhancing drug delivery, cellular uptake, and accumulation of chemotherapeutic agents to their specific target sites. Rapid elimination from blood circulation is the greatest obstacle that conventional chemotherapeutic agents face on journey to their target sites. Target specific nanoparticles have proven to be a useful tool in efforts to overcome challenges typically encountered by targeting strategies. Development of nanoparticles loaded with chemotherapeutic agents can allow for more selective tumor targeting, extended drug circulation times, and reduced drug-associated toxicity. Nanoparticles can significantly improve the treatment efficacy in retinoblastoma. The purpose of this review is to discuss the important characteristics and differences of nano delivery systems used against cellular and in vivo models of retinoblastoma, particularly as they relate to the popular Y79 retinoblastoma cell line.

show abstract

Section: Effective Treatment Approachmentioning

confidence: 92%

“…The study revealed an improved growth inhibitory effect when compared to native carboplatin. 32 Nanoparticles offer interesting possible solutions for the treatment for retinoblastoma. For example, the anticancer drug nutlin-3a, activates the tumor suppressor gene p53.…”

Section: Effective Treatment Approachmentioning

confidence: 99%

An Overview of Nanoparticles for Treatment of Retinoblastoma: Disease Characteristics and Experimental Approaches

Patel

Conte

Luo

et al. 2022

MRAJ

View full text Add to dashboard Cite

show abstract

Weibull β value for the discernment of drug release mechanism of PLGA particles

Martín-Camacho

Rodríguez-Barajas

Sánchez-Burgos

et al. 2023

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Advanced Technologies of Drug Delivery to the Posterior Eye Segment Targeting Angiogenesis and Ocular Cancer

Ansari¹,

Kulkarni²,

Singh³

2024

Crit Rev Ther Drug Carrier Syst

View full text Add to dashboard Cite

Retinoblastoma (RB), a childhood retinal cancer is caused due to RB1 gene mutation which affects the child below 5 years of age. Angiogenesis has been proven its role in RB metastasis due to the presence of vascular endothelial growth factor (VEGF) in RB cells. Therefore, exploring angiogenic pathway by inhibiting VEGF in treating RB would pave the way for future treatment. In preclinical studies, anti-VEGF molecule have shown their efficacy in treating RB. However, treatment requires recurrent intra-vitreal injections causing various side effects along with patient nonadherence. As a result, delivery of anti-VEGF agent to retina requires an ocular delivery system that can transport it in a non-invasive manner to achieve patient compliance. Moreover, development of these type of systems are challenging due to the complicated physiological barriers of eye. Adopting a non-invasive or minimally invasive approach for delivery of anti-VEGF agents would not only address the bioavailability issues but also improve patient adherence to therapy overcoming the side effects associated with invasive approach. The present review focuses on the eye cancer, angiogenesis and various novel ocular drug delivery systems that can facilitate inhibition of VEGF in the posterior eye segment by overcoming the eye barriers.

show abstract

Carboplatin-loaded surface modified-PLGA nanoparticles confer sustained inhibitory effect against retinoblastoma cell in vitro

Cited by 3 publications

References 0 publications

An Overview of Nanoparticles for Treatment of Retinoblastoma: Disease Characteristics and Experimental Approaches

An Overview of Nanoparticles for Treatment of Retinoblastoma: Disease Characteristics and Experimental Approaches

Weibull β value for the discernment of drug release mechanism of PLGA particles

Advanced Technologies of Drug Delivery to the Posterior Eye Segment Targeting Angiogenesis and Ocular Cancer

Contact Info

Product

Resources

About